Agoracom Blog Home

Posts Tagged ‘small cap stocks’

« Older Entries
Newer Entries »

Empower Clinics $CBDT.ca Announces Significant Patient Growth in February 2020 with Visits Increasing by 800% $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 7:02 AM on Wednesday, March 4th, 2020
  • Patient visits in corporate clinics increased by 800% in February 2020 versus the same period in 2019
  • Total patient visits of 1,817 in February 2020 compared to 227 in February 2019

VANCOUVER, BC / March 4, 2020 / EMPOWER CLINICS INC. (CSE: CBDT) (OTC: EPWCF) (Frankfurt 8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented life sciences company, is pleased to announce that patient visits in corporate clinics increased by 800% in February 2020 versus the same period in 2019, with total patient visits of 1,817 in February 2020 compared to 227 in February 2019.

“Patient volumes have remained strong to start the year in all clinics, continuing on our push for a record first quarter.” said Dustin Klein, SVP Business Development and Director of Empower. “Operational excellence each day, combined with exemplary care for the patient, sets us apart in the markets we serve.”

The Company also has received numerous inquiries with both positive and supportive sentiment, after the recent announcement of the Company’s intention to create a psilocybin and psychedelics division.

“Getting positive reinforcement from researchers, physicians, advocates and practitioners about our intention to enter this developing field of study, gives me confidence that we have made the correct decision to leverage our corporate assets for psilocybin and psychedelics research and development.” said Steven McAuley, Chairman & CEO of Empower.

ABOUT EMPOWER

Empower is a vertically-integrated health & wellness brand with it’s first hemp-derived CBD extraction facility under development, the Company produces its proprietary line of cannabidiol (CBD) based products and distributes products through company owned and franchised clinics, with wholesale partnerships, online channels and with new retail opportunities nationwide in the U.S. The company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley

CEO

[email protected]

604-789-2146

Investors: Dustin Klein
SVP, Business Development
[email protected]
720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Tags: , , , , ,
Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca Announces Significant Patient Growth in February 2020 with Visits Increasing by 800% $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

CLIENT FEATURE: CardioComm Solutions $EKG.ca – Putting Your Heartbeat Into The Cloud For Instant Diagnostics $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 6:03 PM on Monday, March 2nd, 2020

Global Leaders in Mobile  ECG Connectivity

  • 20 years of medical credibility licensing technologies to hospitals, physicians, remote patient monitoring  platforms, research groups and commercial call centers
  • Sold into > 20 countries, with the largest customer base located in the US
  • Class II medical device clearances and device agnostic for collecting, viewing, recording, analyzing and  storing of ECGs for management of patient and consumer health
  • ECG solutions for both consumer (OTC) and medical (Rx) markets
  • Owns all IP and source code
  • Market expert contributor for reports in m‐health, mobile cardiac monitoring and new advances in  consumer health and wellness monitoring

Recent Highlights

Physician Groups Order The Heartcheck(TM) Cardibeat For In-Home Arrhythmia And Atrial Fibrillation Monitoring

  • Confirms market traction with orders being placed by physician groups for the newly launched HeartCheck™ CardiBeat Handheld ECG monitor and GEMS™ Mobile Smartphone app for prescribed in-home arrhythmia monitoring.
  • Partners in Advanced Cardiac Evaluation, the largest arrhythmia practice in Ontario (Canada) placed a first order of the HeartCheck™ CardiBeat Handheld ECG monitors and is recommending its patients to use the devices for one year of in-home, self-monitoring with an emphasis on detecting a recurrence of Atrial Fibrillation following cardiac ablation treatment for AF.

Industry News

Company Accolades

FULL DISCLOSURE: CardioComm Solutions Inc. is an advertising client of AGORA Internet Relations Corp.

Tags: , , , , , ,
Posted in AGORACOM Client Feature, All Recent Posts, CardioComm Solutions | Comments Off on CLIENT FEATURE: CardioComm Solutions $EKG.ca – Putting Your Heartbeat Into The Cloud For Instant Diagnostics $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

#Wearables For #Mhealth Apps: The Future Of The Healthcare Industry SPONSOR: CardioComm Solutions $EKG.ca – $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 3:00 PM on Monday, March 2nd, 2020

SPONSOR: CardioComm Solutions (EKG: TSX-V) – The heartbeat of cardiovascular medicine and telemedicine. Patented systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals and call centres to access and manage patient information in a secure and reliable environment.

Wearables For Mhealth Apps: The Future Of The Healthcare Industry

  • While the benefits of mHealth apps and wearables among the common users are well known, the benefits of its use among healthcare professionals are still unknown
  • There are various ways health wearables are changing the healthcare industry, streamlining diagnosis and treatment

By: Olivia Taylor

There’s a new technology trend in the market every day. Some of these succeed, while some of these fail to make their mark. But what happens when two very successful technology trends come together?

When the wearable technology started to enter the market, not many people gave it a second thought. Whether it’s a Bluetooth headphone, Google glasses or Apple watch. The ordinary “not-so-tech-savvy” users were not very enthusiastic about investing in these devices until they connected with another major trend in the market, the mHealth apps.

Due to the emergence of smartphones, users have been using mHealth apps for a long time already. These usages were limited to recording their health details and whatnot. But with the wearable technology, they now have a hands-on way of tracking various aspects of their health in real-time. Whether it is their blood pressure or heart rate per minute, with the integration of wearable technology in mHealth apps, the users now have the perfect way of keeping track of their health.

It will, however, be wrong of us to assume that mHealth app wearables are only limited to modern fitness bands such as Fitbits and Mi bands. Wearable devices for mHealth apps have crossed the boundaries of simply keeping track of fitness and reached healthcare professionals to help them with various complex medical diagnoses and problems. What are these problems? Let’s have a look.

Wearable Trends In mHealth App: How It Helps The Professionals?

While the benefits of mHealth apps and wearables among the common users are well known, the benefits of its use among healthcare professionals are still unknown. There are various ways health wearables are changing the healthcare industry, streamlining diagnosis and treatment.

Here are a few examples of how the emerging technology of wearables in mHealth application are helping out the professionals in the field.

Increasing Efficiency During Surgery

If we are talking about the benefits of wearables in the healthcare industry, we need to start with the increased efficiency during surgery. Performing surgery on the human body is a complicated enough procedure, but now the integration of wearables is helping the surgeons to perform even the most complicated surgeries with precision.

While previously the approach to surgery was an “Open” approach, today thanks to wearable and mHealth tech, the surgeons can apply the minimally invasive methods of performing surgery. This way they can prevent a lot of blood loss, shorter recovery time for the patients and fewer chances of infections.

Whether we are talking about the development of robotic wearable arm for surgeries or the simple application of Google Glasses, the wearable tech in mHealth apps are surely making the otherwise complex field of surgeries a lot easier to navigate.

Wearable IoT in the Healthcare Industry

IoT is already an extremely popular technology trend in the market. And when you add that to the wearable mHealth trends in the healthcare industry, you have plenty of efficient applications of wearable IoT in healthcare.

Besides the more obvious use of IoT to locate medical instruments throughout the building, the wearable IoT devices are helping the medical professionals to locate doctors within seconds during an emergency. These devices are also helping with the treatment of patients, as it is evident from the popularity of smart continuous glucose monitors and connected inhalers. With these connected devices it is easier for the medical professionals to not only diagnose the patient but treat them with accuracy.

The wearable IoT devices in the healthcare industry have proven that the amalgamation of technology with the healthcare industry is going to be extremely beneficial for both the patients as well as the doctors.

Wearable Biosensors

One of the most futuristic applications of wearable technology for mHealth apps is wearable biosensors. These small sensors are capable of providing continuous physiological information through non-invasive methods. With these sensors, healthcare professionals can measure the biochemical markers in biofluids like sweat, blood, tears, saliva, etc to keep track of the patient’s health and help the physicians to provide better treatment.

Not just for healthcare, these wearable sensors are being used by the sportspeople and military as well. With Biosensors like these, the military could actually monitor the health of their troops on the field. The medical experts can keep track of any chemical or infectious agent the soldiers can come across, providing added safety and advantage in the wars. For athletes, wearable biosensors make it easy to keep track of their vitals during training. They can easily gain a competitive edge with biosensors designed to track their health and health and performance.

Creating a Proactive Healthcare Environment

The present-day healthcare system is more reactive than proactive. The patients only go to healthcare professionals after they show the symptoms of illness. While this might be more convenient for a lot of people, it is sometimes too late for the doctors to do anything about the illness. And that’s why using medical wearables can be a perfect way of changing the healthcare system into a proactive one so that the patients can be treated ahead of time.

With proactive healthcare systems, healthcare professionals can keep a close track of the patient’s health and act fast when any irregularities occur. This way the doctors can be prepared before any medical emergency makes the scenario even worse.

Easy Monitoring of the Patients

The emerging trend of wearables for mHealth applications has now made it easy for healthcare professionals to monitor the vitals of the patients. Sensors such as the ECG sensor, health patches are the perfect gadgets to monitor vulnerable patients in real-time.

Not only among the doctors but the popularity of these wearables are increasing among the common users too. Healthcare wearables are helping them immensely to take care of their ill family members by taking proactive measures when any kind of irregularities occur in their vitals. These sensors are also perfect for those who’ve had serious surgery. The medical services providers can track their recovery even when they are at home. This way the patients don’t have to spend a whole lot of time in the hospital for recovery.

Source: https://bdaily.co.uk/articles/2020/02/20/wearables-for-mhealth-apps-the-future-of-the-healthcare-industry

Tags: , , ,
Posted in CardioComm Solutions | Comments Off on #Wearables For #Mhealth Apps: The Future Of The Healthcare Industry SPONSOR: CardioComm Solutions $EKG.ca – $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

PyroGenesis $PYR.ca Announces New Website Launch $LMT $RTN $NOC $UTX $HPQ.ca $DDD.ca $SSYS $PRLB

Posted by AGORACOM-JC at 3:29 PM on Thursday, February 27th, 2020
  • Announced the launch of its redesigned website taking effect this March
  • Website has been revamped to include new features and improved functionality that provide instant access to essential information and features geared towards PyroGenesis’ interested parties 

MONTREAL, Feb. 27, 2020 — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX-V: PYR) (OTCQB: PYRNF) (FRA: 8PY), a high-tech company, (the “Company”, the “Corporation” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch products, is proud to announce the launch of its redesigned website taking effect this March. The website has been revamped to include new features and improved functionality that provide instant access to essential information and features geared towards PyroGenesis’ interested parties.  

PyroGenesis’ new website will be continuously updated with business developments, events, company presentations, media mentions and press releases. Once launched, visitors are encouraged to explore the website and sign up for direct emails from the Company.

“We are happy to unveil our redesigned website which offers a clean and modern design providing a more comprehensive understanding of PyroGenesis’ technologies,” said Mr. P Peter Pascali, CEO and President of PyroGenesis. “We believe that this website will allow our visitors to have a very informative experience as we continue to grow and increase our market presence. I trust the timing of this news release is not lost on our readers.”

Of note, it is possible that, during this transition, PyroGenesis’ website may be under maintenance for a period up to 24 hours. It is also important to note that, during the weeks following the launch date, the redesigned website may be experiencing some minor technical adjustments. PyroGenesis’ team will work diligently to ensure all issues are resolved in a timely manner. The company looks forward to hearing your comments and feedback.

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc., a high-tech company, is the world leader in the design, development, manufacture and commercialization of advanced plasma processes and products. We provide engineering and manufacturing expertise, cutting-edge contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Our core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Our operations are ISO 9001:2015 and AS9100D certified, and have been since 1997. PyroGenesis is a publicly-traded Canadian Corporation on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace. For more information, please visit www.pyrogenesis.com

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PyroGenesis Canada Inc.

For further information please contact:

Rodayna Kafal, Vice President Investors Relations and Strategic Business Development
Phone: (514) 937-0002, E-mail: [email protected] 

RELATED LINK: http://www.pyrogenesis.com/

Tags: , , , , ,
Posted in All Recent Posts, PyroGenesis Canada Inc. | Comments Off on PyroGenesis $PYR.ca Announces New Website Launch $LMT $RTN $NOC $UTX $HPQ.ca $DDD.ca $SSYS $PRLB

Empower Clinics $CBDT.ca – CBD consumption to rise across the treatment of neurological conditions $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 1:53 PM on Thursday, February 27th, 2020

SPONSOR:

Why Empower Clinics

  • A leading owner/operator of physician staffed health and pain management clinics.
  • Patient database of over 165,000 patients 
  • Platform generating $1.4M USD (9 months ending Sept. 30, 2019)
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Recently launched CBD extraction facility
  • First extraction system capacity = 2,300 Kg per year.
  • CBD based products are poised to be a $20B global industry by 2022
  • Medical cannabis is poised to be a $100B global industry by 2025
  • Company to Create Psilocybin and Psychadelics Division Leveraging Corporate Wellness Clinics and Franchise Clinic Network

CBD consumption to rise across the treatment of neurological conditions

Research shows that CBD consumption for the treatment of neurological conditions is set to rise.

  • With an exponential rise in the availability of CBD products and public opinion towards it becoming more positive over the past decade, the consumption of the ingredient has exploded.
  • Global Market Insights, Inc., forecasts that global cannabidiol market size will be worth more than $89bn by 2026.

By: Health Europa

However, the industry will need to overcome the complex regulatory landscape as well as quality and supply challenges in the near future.

Over the past few years, cannabidiol, or CBD, has caught the public’s imagination as an ingredient presenting a range of health benefits when infused in various consumables. More and more individuals worldwide are now vouching for its effectiveness in terms of alleviating certain chronic illnesses and treating several health conditions.

CBD has conquered industry after industry, from pharmaceuticals to personal care and cosmetics, food and beverages, and nutraceuticals.

Cannabidiol is the legal and non-psychoactive counterpart of tetrahydro cannabidiol (THC), the chemical compound responsible for cannabis’s psychological effects. CBD is the second most-commonly used active ingredients of cannabis. The cannabinoid is derived directly from the hemp plant, a cousin of the cannabis plant, and forms an essential component of medical cannabis.

CBD regulatory landscape in Europe

Factors such as population growth, nationalised healthcare, GDP, and cultural historic use of CBD in many European countries make the continent an attractive market for global producers of both medical and retail cannabis-based products. Hemp cultivation in the region has witnessed a massive upsurge in recent years; the European Union (EU) constitutes more than 25% of the global hemp production.

In July last year Epidiolex CBD oil received a positive recommendation for marketing approval from the European Medicines Agency (EMA) for the treatment of seizures. EMA’s Human Medicines Committee (CHMP) approved the oral solution for use with clobazam for the treatment of seizures associated with Dravet syndrome or Lennox-Gastaut syndrome in patients aged two or more.

The European Commission granted marketing approval to Epidyolex, the trade name for Epidiolex in Europe, in September 2019. Epidiolex is the only federally-approved CBD product in the U.S.

Additionally, the use of CBD in cosmetics is harmonised within the European Cosmetic Regulation 1223/2009. The regulation prohibits the use of cannabis and its derivatives in cosmetic products. Essentially, EU prohibits the use of CBD derived naturally from cannabis plants. However, the use of hemp-derived or synthetically-produced cannabidiol is approved.

Europe CBD market is poised to witness monumental growth in the forthcoming years on account of surging consumer demand for safe-strength CBD products that are easily available in their normal retail environments and cultivated, extracted, processed and labelled as per the European standards.

Growing burden of neurological diseases in Europe

Europe has witnessed a growing occurrence of various neurological conditions in recent years. These include epilepsy, migraine, stress, anxiety, and numerous sleeping disorders. An expanding geriatric population base indicates rising incidences of these conditions. Citing data from the European Brain Council, more than 220 million people in Europe suffer from at least one neurological condition, which is more than the populations of France, Germany, and the Great Britain combined.

Described below are some of the most prevalent neurological conditions in Europe and the effectiveness of CBD in their treatment.

  • Stress and anxiety – Nearly 25% of the European population suffers from stress, anxiety or depression each year. The effectiveness of CBD products as anti-anxiety nutraceuticals is backed with plenty of research, however there is still a long way to go. Several clinical trials have provided considerable evidence of cannabidiol’s usefulness for the treatment of generalised anxiety disorder (GAD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), social anxiety disorder, and panic disorder;
  • Migraine – Migraine currently affects more than 11% of the global population. The social societal burden of migraine in Europe is an approximately €27bn per year. While pain medications are known to help temporarily alleviate the symptoms of migraine, they can have several side-effects. Research concerning the use of cannabidiol for migraine is limited however a number of laboratory studies suggest that CBD oil may help reduce all types of acute and chronic pain, including migraine; and
  • Seizures – In Europe, close to six. million people suffer from epilepsy, while 15 million people will have at least one seizure at some point during their lifetime. Numerous research studies over the years have demonstrated the benefits and effectiveness of hemp-derived CBD products in patients with epilepsy who have not responded to traditional treatment.

Surging popularity of cannabidiol among boomers along with ongoing research and development into its potential health benefits will augment CBD market forecast. More and more boomers are adding CBD to their health regimes to help reduce stress and anxiety, get better sleep, and alleviate chronic pain. Increasing awareness towards the safety and efficacy of cannabidiol products will drive future CBD industry trends.

Source: https://www.healtheuropa.eu/cbd-consumption-to-rise-across-the-treatment-of-neurological-conditions/98105/

Tags: , , , , , ,
Posted in All Recent Posts, Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca – CBD consumption to rise across the treatment of neurological conditions $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

AGORACOM – 5 Simple & Powerful Ways For Small Cap Companies To Use Social Media

Posted by AGORACOM-JC at 4:21 PM on Wednesday, February 26th, 2020

If you are a small cap CEO, Director or Investor Relations Officer in North America, my 23 minute interview with James Black of the Canadian Securities Exchange (CSE) is the most important podcast you will listen to in 2020. Not because I am the guest but because of what I have to say.

Why does what I say matter? AGORACOM surpassed 600 million page views this year, we’re averaging over 4.5M views per month on Twitter and we’ve served over 300 clients. As such, the powerful information in this podcast comes from a deep understanding of both social media, why small cap companies are failing at it and what the serious implications are of that failure.

Make no mistake about it, this isn’t some generic social media discussion. James and I go deep and I hit hard because that is what good friends do. I’m sounding the alarm because of the massive implications if I don’t.

The good news is that, if you are not an AGORACOM client, you can turn this ship around but you have to do it now and that can only be done by understanding why small caps are failing today.

I suggest that your entire management team listens to it and discusses it. Then let’s have a call to discuss what can be done.

The beauty of this audio format is you can listen to it at work or in your car / subway to and from work. I’ve done the hard work presenting this powerful information, all you have to do is press play.

Thank-you and I look forward to discussing this with you and potentially working together in 2020. Our cashless and fully compliant shares for services program should make the decision an easy one.

Tags: , , ,
Posted in All Recent Posts | Comments Off on AGORACOM – 5 Simple & Powerful Ways For Small Cap Companies To Use Social Media

PyroGenesis $PYR.ca Provides Update on Payment Terms with Drosrite International LLC $LMT $RTN $NOC $UTX $HPQ.ca $DDD.ca $SSYS $PRLB

Posted by AGORACOM-JC at 1:23 PM on Wednesday, February 26th, 2020
  • Announced today that, further to its press release dated October 9th, 2019, the payment terms noted therein have been adjusted pro rata to mirror Drosrite International LLC’s cash flow as outlined in their press release1 dated January 27th, 2020. 
  • “With this announcement, I am happy to also report that it seems all impediments to the payment process have been addressed,” said Mr. P. Peter Pascali, President and CEO of PyroGenesis. “We look forward to having the DROSRITE™ technology installed in one of the premier facilities in the world.”

MONTREAL, Feb. 26, 2020 — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX-V: PYR) (OTCQB: PYRNF) (FRA: 8PY), a high-tech company, (the “Company”, the “Corporation” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch products, announces today that, further to its press release dated October 9th, 2019, the payment terms noted therein have been adjusted pro rata to mirror Drosrite International LLC’s (“DI” or the “Client”) cash flow as outlined in their press release1 dated January 27th, 2020. 

“With this announcement, I am happy to also report that it seems all impediments to the payment process have been addressed,” said Mr. P. Peter Pascali, President and CEO of PyroGenesis. “We look forward to having the DROSRITE™ technology installed in one of the premier facilities in the world.”

DI is a US based private company duly constituted and existing under the laws of the State of Delaware, providing state-of-the-art waste management technologies to the aluminum industry. DI is duly licensed by PyroGenesis to manufacture, market, sell and distribute DROSRITE™ systems and technology to the Kingdom of Saudi Arabia, and certain other countries in the Middle East, on an exclusive basis. All DROSRITE™ systems supplied by DI are manufactured in the USA.

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc., a high-tech company, is the world leader in the design, development, manufacture and commercialization of advanced plasma processes and products. We provide engineering and manufacturing expertise, cutting-edge contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Our core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Our operations are ISO 9001:2015 and AS9100D certified, and have been since 1997. PyroGenesis is a publicly-traded Canadian Corporation on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace. For more information, please visit www.pyrogenesis.com

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PyroGenesis Canada Inc.

For further information please contact:

Rodayna Kafal, Vice President Investors Relations and Strategic Business Development
Phone: (514) 937-0002, E-mail: [email protected]

RELATED LINK: http://www.pyrogenesis.com/

__________________________

Tags: , , ,
Posted in PyroGenesis Canada Inc. | Comments Off on PyroGenesis $PYR.ca Provides Update on Payment Terms with Drosrite International LLC $LMT $RTN $NOC $UTX $HPQ.ca $DDD.ca $SSYS $PRLB

Empower Clinics $CBDT.ca – CBD Sales Predicted to Grow, #cannabis and #cannabidiol #CBD products reached $14 billion in 2019 $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 12:05 PM on Wednesday, February 26th, 2020

SPONSOR:

Why Empower Clinics

  • A leading owner/operator of physician staffed health and pain management clinics.
  • Patient database of over 165,000 patients 
  • Platform generating $1.4M USD (9 months ending Sept. 30, 2019)
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Recently launched CBD extraction facility
  • First extraction system capacity = 2,300 Kg per year.
  • CBD based products are poised to be a $20B global industry by 2022
  • Medical cannabis is poised to be a $100B global industry by 2025
  • Company to Create Psilocybin and Psychadelics Division Leveraging Corporate Wellness Clinics and Franchise Clinic Network

CBD Sales Predicted to Grow, Market Analysis Finds

  • U.S. retail sales of cannabis and cannabidiol (CBD) products reached $14 billion in 2019
  • On pace to increase 18% per year to $33 billion in 2024

By WholeFoods Magazine Staff

Rockville, MD—U.S. retail sales of cannabis and cannabidiol (CBD) products reached $14 billion in 2019, and are on pace to increase 18% per year to $33 billion in 2024, according to data published in a new report from Packaged Facts titled Cannabis and CBD: U.S. Retail Market Trends and Opportunities.

The most common delivery format for cannabis, the flower—smoked as buds or as cigarettes—accounts for nearly 40% of retail sales, according to a press release. Vaporizer cartridges with concentrated THC or CBD compounds takes the second largest share, but it’s falling, as concerns about vaping-related lung illnesses rise. Edibles and topicals are predicted to rise, and to rise quickly, as they stand to benefit the most from legalization of hemp-based CBD; major retailers are already offering CBD-infused food and beverages, as well as CBD-infused cosmetics.

The report analyzes cannabis and cannabis-related retail trends and opportunities in the U.S., with a focus on multi-state cannabis dispensary operators and food and beverage introductions, as well as market trends by state. It also includes a detailed analysis of cannabis-related legal and regulatory trends at the federal and state levels. The report can be purchased here.

Source: https://wholefoodsmagazine.com/suppliers/news-suppliers/cbd-sales-predicted-to-grow-market-analysis-finds/

Tags: , , , , , , ,
Posted in All Recent Posts, Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca – CBD Sales Predicted to Grow, #cannabis and #cannabidiol #CBD products reached $14 billion in 2019 $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

#Apple, #J&J Launch New #Mhealth Study Targeting #Wearables and #AFib SPONSOR: CardioComm Solutions $EKG.ca – $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 5:20 PM on Tuesday, February 25th, 2020

SPONSOR: CardioComm Solutions (EKG: TSX-V) – The heartbeat of cardiovascular medicine and telemedicine. Patented systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals and call centres to access and manage patient information in a secure and reliable environment.

Apple, J&J Launch New mHealth Study Targeting Wearables and AFib

By Eric Wicklund

  • Apple is partnering with Johnson & Johnson on a new mHealth study to determine whether the Apple Watch and an accompanying app can help reduce the risk of stroke in older Americans.
  • The Heartline Study is open to the more than 40 million seniors enrolled in Medicare
  • Goal is to determine whether the ECG sensor and app on the Apple Watch can accurately detect the presence of atrial fibrillation, a key indicator of stroke susceptibility.

The Heartline Study is open to the more than 40 million seniors enrolled in Medicare. Its goal is to determine whether the ECG sensor and app on the Apple Watch can accurately detect the presence of atrial fibrillation, a key indicator of stroke susceptibility.

“Right now, we rely on symptoms – such as quivering, fluttering or irregular heart rhythm – to detect AFib,” Michael Gibson, MD, CEO of the Baim Institute for Clinical Research, founder of the Perfuse Study Group at Harvard Medical School and a co-leader on the study, said in a story on the J&J website. “But the hope is that a wearable device could detect an irregular heart rhythm earlier, since people may not be able to recognize symptoms without assistance. It could act like a warning light that allows a mechanic to detect whether something’s wrong before the car actually breaks down.”

Gibson will head the study alongside John Spertus, MD, the Daniel J. Lauer/Missouri Endowed Chair in Metabolic and Vascular Disease Research at the University of Missouri at Kansas City.

This study follows on the heels of the Apple Heart Study, to date the largest analysis of mHealth data from a wearable device. Launched in 2017 by the Stanford University School of Medicine, Apple and American Well, the study attracted almost 420,000 participants and laid the groundwork for the viability of ECG sensors for detecting AFib.

“The study’s findings will help patients and clinicians understand how devices like Apple Watch can play a role in identifying atrial fibrillation, a deadly and often undiagnosed disease,” Mintu Turakhia, MD, an associate professor of cardiovascular medicine at Stanford, said when the study’s results were released in 2019. “Additionally, these important findings lay the foundation for further research into the use of emerging wearable technologies in clinical practice and demonstrate the unique potential of large-scale app-based studies.”

But that study raised concerns because it wasn’t focused on one particular population, leading to worries that such digital health tools could cause more harm than good.

This time around, investigators are homing in on a population facing a significant risk of stroke.

“Each year more than 795,000 people have a stroke in the US, and some studies have shown that many people would rather die than live with the aftereffects of a disabling stroke,” Gibson said. “Secondly, we have an aging population, so there are more and more older patients around the world. These are exactly the patients who are at the highest risk of atrial fibrillation, which is associated with a significant increase in the risk of stroke. But the good news is that these strokes may be preventable.”

‘By having the study focus on the highest risk patients, my hope is that we can potentially help participants improve their heart health,” he added.

Participants in the study will use an Apple Watch and Heartline Study app, which alerts the user when the smartwatch detects an irregular heart rhythm and advises him or her to seek advice from a healthcare provider. The app, which also provides information and resources to the user, can be triggered to personalize that information if a care provider confirms an AFib diagnosis or if the user isn’t engaged with the program.

“The decision to take action is the responsibility of the participant, but the Heartline Study app will provide additional prompting and educational materials to help people make informed decisions,” Gibson said.

“I’m excited about this part of the study because, as physicians, we need to get a better handle on how often that lack of action happens,” he added. “While it’s clear that patients often don’t take the medicines they’re prescribed – and, in fact, often don’t even pick them up from the pharmacy – this study could provide more solid data and help us learn more about how often patients don’t respond to warnings about abnormalities in their health.”

In time, he said, researchers hope to understand more about why people might not take part in this type of study and develop patient engagement techniques that promote participation and reduce barriers to care.

Source: https://mhealthintelligence.com/news/apple-jj-launch-new-mhealth-study-targeting-wearables-and-afib

Tags: , , , ,
Posted in CardioComm Solutions | Comments Off on #Apple, #J&J Launch New #Mhealth Study Targeting #Wearables and #AFib SPONSOR: CardioComm Solutions $EKG.ca – $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Empower Clinics $CBDT.ca to Create #Psilocybin and Psychadelics Division Leveraging Corporate Wellness Clinics and Franchise Clinic Network $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 6:10 AM on Tuesday, February 25th, 2020
  • Company intends to utilize its database of 165,000 patients to further psilocybin research, develop new products and partner with global leaders in the field
  • “Empower is uniquely positioned to immediately impact research, develop new products and bring advancements to plant-based therapies, under a framework of rapidly increasing awareness and a movement toward decriminalization of psychedelic treatment options.” said Steven McAuley, Chairman & CEO of Empower

VANCOUVER, BC / February 25, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(OTC:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented life sciences company is pleased to announce it intends to leverage its existing clinic network, the developing franchise brand, its 165,000 patients and product development capability, to create psilocybin and psychedelics subsidiaries.

The Company has been conducting market research on advancements in psilocybin and psychedelics in North America and globally, along with building the business case internally on how to create greater shareholder value, utilizing Company assets that include clinics, patients, physicians and technology.

“There is an undeniable mental health crisis in our country and around the world, that has an ever-increasing, devastating affect on our society.” said Steven McAuley, Chairman & CEO of Empower. “Empower is uniquely positioned to immediately impact research, develop new products and bring advancements to plant-based therapies, under a framework of rapidly increasing awareness and a movement toward decriminalization of psychedelic treatment options.”

Studies conducted by nationally and internationally recognized medical institutions indicate that psilocybin has shown efficacy, tolerability, and safety in the treatment of a variety of mental health conditions, including but not limited to addiction, depression, anxiety disorders, and end-of-life psychological distress.

“Over the past seven years, we have assisted over one hundred thousand patients obtain access to alternative health care and medicinal cannabis. The provision of legal access to psilocybin therapies are perfectly in-line with our philosophy of providing a Scientific Approach to Alternative Medicine™“, said Dustin Klein, SVP Business Development and Director, Empower Clinics Inc. “Clinical trials have shown that psilocybin therapies provide tremendous help with conditions we see everyday in our clinics. It is our responsibility, to make sure we are providing the most up-to-date alternative therapies to our patients and our community.”

The mental health crisis could cost the world $16 trillion by 2030 and according to Future Market Insights; the global behavioral health (non-pharmacological) market is expected to be valued at US$156 billion by 2028.

The United States Food and Drug Administration has determined that preliminary clinical evidence indicates psilocybin may demonstrate substantial improvement over other available therapies for treatment-resistant depression; and granted a Breakthrough Therapy designation for a treatment that uses psilocybin as a therapy for such depression.

The Company also announces it has issued to Haywood Securities Inc., 4,000,000 common shares of the Company (the “Work Fee Shares”) under the financial advisory agreement dated September 25, 2019 (the “Agreement”) based on Haywood Securities Inc. completing the final written SWOT analysis. The shares issued are priced at fair market value of the common shares of the Corporation as at the date of issuance of the Work Fee Shares.

ABOUT EMPOWER

Empower is a vertically-integrated health & wellness brand with it’s first hemp-derived CBD extraction facility under development, the Company produces its proprietary line of cannabidiol (CBD) based products and distributes products through company owned and franchised clinics, with wholesale partnerships, online channels and with new retail opportunities nationwide in the U.S. The company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley
Chairman & CEO
[email protected]
604-789-2146

Investors: Dustin Klein
SVP, Business Development
[email protected]
720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Tags: , , , , , ,
Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca to Create #Psilocybin and Psychadelics Division Leveraging Corporate Wellness Clinics and Franchise Clinic Network $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

« Older Entries
Newer Entries »